INTH-454
Advanced Prostate Cancer (CRPC) and Colorectal Cancer (CRC)
IND-ready / Pre-clinicalActive
Key Facts
Indication
Advanced Prostate Cancer (CRPC) and Colorectal Cancer (CRC)
Phase
IND-ready / Pre-clinical
Status
Active
Company
About Inthera Bioscience
Inthera Bioscience is a private, preclinical-stage biotech developing a novel oncology therapeutic platform. Its lead asset, INTH-454, is a first-in-class small molecule inhibitor of the NELF transcription complex, designed to selectively kill highly proliferative tumor cells by exacerbating their inherent replication stress. The company is IND-ready, with an initial clinical focus on advanced prostate cancer (CRPC) and colorectal cancer (CRC), and is backed by a management team with extensive industry experience and Aglaia Oncology Funds as a key shareholder.
View full company profile